The UEG Week 2026 programme now carries the full abstract of the ABTECT maintenance subgroup analysis (Danese et al.), to be presented orally on Tuesday 20 October, 12:20 CEST, in the session "Looking into the future: Novel therapeutics in IBD (Part 2)". The table is circulating on X this morning.
Link to the abstract and full data table:
What is new and what is not
The totals reconcile exactly with the 1 June topline (clinical remission at week 44: 50.8% on 25 mg and 51.3% on 50 mg vs 10.4% on placebo). The novelty is the split: 41% of the 580 maintenance patients were AT-IR (238) and 59% AT-naive (342), plus a JAK-failure subset and a breakdown by number of prior advanced-therapy failures, none of which had been disclosed so far.
Key figures, week 44 (25 mg / 50 mg vs placebo)
- AT-IR, clinical remission: 34.2% / 42.2% vs 6.9% (delta +28.0 / +33.1 pts, p<0.0001)
- AT-IR, endoscopic remission: 23.7% / 38.9% vs 5.6%
- AT-IR, HEMI: 34.2% / 48.9% vs 6.9%
- AT-naive, clinical remission: 61.5% / 59.0% vs 12.5% (delta +48.1 / +45.1 pts)
- AT-naive, endoscopic remission: 53.0% / 55.2% vs 12.5%
- JAK-failure patients, clinical remission: 28.6% (4/14) / 33.3% (5/15) vs 0% (0/16), p=0.019 and p=0.038
- By line of therapy, clinical remission on 50 mg ranges from 33% to 48% across 1, 2, 3 and 4+ prior advanced-therapy failures
Our read
1. Positive and consistent. The effect holds in the refractory population with a very low placebo rate, and the drug works after JAK failure, a segment the market leader upadacitinib, itself a JAK, cannot address by construction.
2. A clear dose logic emerges. In AT-naive patients 25 mg and 50 mg are equivalent; in AT-IR patients 50 mg separates on the mucosal endpoints (endoscopic remission 38.9% vs 23.7%). This supports filing both doses, as management intends: 25 mg as a front-line maintenance dose, 50 mg for refractory patients.
3. Benchmark. On the overall population, maintenance remission is in line with upadacitinib (Rinvoq 15 mg / 30 mg: 40.4% / 53.6% vs 10.8% at week 52) and endoscopic remission is materially higher (41.5% / 47.7% vs roughly 24% / 26%). Cross-trial comparison, with the usual caveats.
Points the bears will raise
- Sustained remission in AT-IR patients is not significant (p=0.69 and p=0.09) on very small numbers (13 to 23 patients per arm) with an unusually high placebo rate (3/13).
- In the line-of-therapy cuts, several subsets are not significant, including 1 prior failure (p=0.28 and p=0.06) and 25 mg in 4+ failures (delta 0.0). Sample sizes are 9 to 41 patients per arm, and all p-values are nominal.
- The induction gap versus Rinvoq is unchanged: fewer patients enter maintenance.
Market angle
The maintenance data landed in the upside case most sell-side scenarios were built on before the June readout, yet the ADS closed at $91.06 on Friday, some 27% below the $125 July offering price, with the debate focused on skin cancer and labelling. This abstract does not address that debate, but it strengthens the positioning argument for later lines and post-JAK use, which matters for both the launch case and strategic interest. The next catalysts are the UEG presentation on 20 October and the NDA submission targeted for Q4 2026.
Source: UEG Week 2026 programme, abstract "Efficacy of obefazimod in phase 3 ABTECT-Maintenance trial: results of 44-week therapy in subsets of patients with and without prior inadequate response to advanced therapies", Danese S. et al.
Best regards,
Laurent Chekroun